Abstract: The presence of a nucleic acid target, molecule or ligand can be detected by hybridization, antigen-antibody reaction or receptor-ligand binding. This is reported by the strategic positioning of a first probe and a second probe attached to a small particle of electrical conductor, which closes an electrical circuit, thereby reporting the event. A myriad of potential applications of this technique include the identification and detection of small amounts of nucleic acids by hybridization, the detection of molecules such as toxins and carcinogens by antigen-antibody reaction and the detection of other molecules by receptor-ligand interaction. The method can also be adapted to assay the quantity of a given substance using the principle of competitive binding.
Abstract: The present invention discloses a process for efficient production of 2-amino-5-hydroxypropiophenone corresponding to the AB ring part of camptothecin (CPT) skeleton, which is a key intermediate useful for the total synthesis of camptothecin analogs including 7-Ethyl-10-hydroxy camptothecin and novel intermediates thereof.
Abstract: This invention provides a method for treating tumor in a subject comprising administering to the subject an effective amount of: (1) VNP40101M, or its equivalent; and (2) a nucleoside, or a nucleoside analog. This invention also provides a method for inhibiting tumor cell growth comprising contacting the tumor cell with effective amounts of: (1) VNP40101M, or its equivalent; and (2) a nucleoside, or a nucleoside analog. The present invention relates to the treatment of cancer, comprising administering to a subject in need thereof an effective amount of VNP40101M in combination with a nucleoside.
Type:
Grant
Filed:
March 25, 2005
Date of Patent:
October 20, 2009
Assignee:
Vion Pharmaceuticals, Inc.
Inventors:
Ivan King, Mario Sznol, Michael Belcourt, Li-Mou Zheng
Abstract: The present invention provides a compound of pyrazolo[3,4-d]pyrimidine having the formula wherein: X=N; R=H, alkylthio, or aminoalkylthio; R1=NHcyclopropyl, NHC3H7, NHC4H9, N(CH2CH3)2, NHCH2CH2OC2H5, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, NHcyclohexyl, 1-hexahydroazepinyl, NHCH2C6H5, or NHCH2CH2C6H5; wherein R3=H, halogen, or alkyl and R5=Cl, Br or OH.
Type:
Grant
Filed:
May 26, 2004
Date of Patent:
September 15, 2009
Assignee:
Universita degli Studi di Siena
Inventors:
Francesco Bondavalli, Maurizio Botta, Olga Bruno, Fabrizio Manetti, Silvia Schenone, Fabio Carraro
Abstract: This invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and, therefore, is useful in preventing and treating viral diseases and cancers. This invention also provides an artificial gene which codes for the super-compound interferon or its equivalent. Finally, this invention provides methods for producing recombinant super-compound interferon or its equivalent and various uses of said interferon.
Abstract: The present invention provides a Luo Han Guo whole fruit extract prepared by a process that includes extracting the peel and pulp of Luo Han Guo fruits by boiling water. The resulting whole fruit extract can be formulated into a sugar-free, low calorie, low glycemic index syrup or jam comprising the Luo Han Guo whole fruit extract and sugar alcohols (polyols).
Type:
Grant
Filed:
September 20, 2006
Date of Patent:
August 18, 2009
Assignee:
Frisun, Inc.
Inventors:
Yuan Shi, Yvonne H. Zhang, Michael Peng
Abstract: Disclosed is a discretionarily adjustable friction force block and tackle balance system comprising a housing and an adjustable break, wherein means are provided for adjusting the friction force between an inner surface of the housing and the adjustable break. An adjustable balance system comprising a housing, a floating anchor assembly, a fixed anchor assembly, a cord, and an elastic suspension is also disclosed. In an embodiment, the housing is a 3-side or 4-side tube or channel. There is at least one elongated hole or slit on at least one surface of said housing. An adjustable break is mounted inside the floating anchor subassembly. Moving the window sash also causes the floating anchor subassembly to move. When the floating anchor subassembly is moved to a position just under elongated hole on the said housing, the adjust screw installed in the adjustable break is exposed.
Abstract: The present invention discloses a seal and connection device between train compartments comprised of a ? shaped rubber groove having two groove walls and a groove bottom. A width between the two groove walls is substantially equal to that of a slit between two neighboring compartments. The two groove walls can be fixed to ends of the two neighboring compartments respectively and the groove bottom are extended toward two ends thereof to form groove brims so that the groove brims can abut against end side walls of the compartments tightly.
Abstract: This invention also provides a method for treating a cancer subject comprising administering to the subject a combination of ATP-depleting agents at concentrations which deplete the ATP level to, or close to, at least 15% of normal in cancer cells wherein at least one of the ATP-depleting agents is a mitochondrial ATP-inhibitor, a methylthioadenosine phosphorylase inhibitor or an inhibitor of De Novo purine synthesis other than 6-Methylmercaptopurine riboside, wherein said composition produces a substantially better effect than a composition without at least one of the ATP-depleting agents: a mitochondrial ATP-inhibitor, a glycolytic inhibitor, a methylthioadenosine phosphorylase inhibitor and an inhibitor of De Novo purine synthesis other than 6-Methylmercaptopurine riboside.
Type:
Grant
Filed:
June 13, 2003
Date of Patent:
April 7, 2009
Assignee:
Sloan-Kettering Institute for Cancer Research
Inventors:
Daniel S. Martin, Joseph R. Bertino, Jason Koutcher
Abstract: Novel compounds such as compounds designated herein as Y or Y3, Y1, Y2, Y8, Y9 and Y10 are disclosed. These compounds have anticancer activity. The compounds of the present invention are obtainable from plants in the sapindaceae family, such as Xanthoceras sorbifolia, or other natural sources or products. The compounds of the present invention may also be synthesized chemically.
Abstract: This invention provides a composition comprising an effective amount of (1-3)-?-glucan derived from barley capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject.
Type:
Grant
Filed:
July 16, 2003
Date of Patent:
March 24, 2009
Assignee:
Sloan-Kettering Institute for Cancer Research
Abstract: A method for selecting an intraocular lens for an aphakic eye that has previously been subjected to refractive surgery by calculating the required power of an IOL to provide the desired refraction using a known formula, and then applying an adjustment based upon the spherical equivalence of the eye prior to refractive surgery.
Abstract: This invention provides composition comprising a triterpenoidal saponin, comprising two side groups attached to carbon 21, and 22 of triterpenoidal saponin backbone. This invention provides a composition for inhibiting skin or ovarian tumor cell growth, comprising an appropriate amount of said compound.
Abstract: This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Ley, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject.
Type:
Grant
Filed:
January 6, 2004
Date of Patent:
January 20, 2009
Assignee:
Sloan-Kettering Institute for Cancer Research
Inventors:
Philip O. Livingston, Govindaswami Ragupathi, Samuel J. Danishefsky
Abstract: A process for the resolution of isomeric tramadol mixtures comprising: providing a purification stock comprising both cis and trans tramadol; contacting the purification stock with an acid under conditions effective to form an acid salt of the cis and trans tramadol in the purification stock; and separating the cis tramadol acid salt from the trans tramadol to obtain a purified cis tramadol acid salt; and optionally converting the cis tramadol acid salt to cis tramadol or to a pharmaceutically active salt thereof.
Abstract: This invention provides a composition comprising an effective amount of (1-3),(1-4)-?-glucan derived from barley capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject.
Type:
Grant
Filed:
August 31, 2005
Date of Patent:
December 9, 2008
Assignee:
Sloan-Kettering Institute for Cancer Research
Abstract: The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).
Type:
Grant
Filed:
March 17, 2005
Date of Patent:
November 18, 2008
Assignee:
Vion Pharmaceuticals, Inc.
Inventors:
David G. Bermudes, Ivan C. King, Caroline A. Clairmont, Michael Belcourt
Abstract: This invention provides an apparatus for growing cells under static or dynamic physiological pressure which contains a cell culture cassette having a cassette frame; two side walls secured to each side of the cassette frame to form a cell growing chamber, and at least one side wall comprises a cell growth surface. The apparatus also contains a means for adjusting fluid pressure or flow, for providing culture media or cell culture, or for sampling cell culture or culture media within the cell growing chamber. The apparatus further contains an adapter which contains two side assemblies where each side assembly includes a frame with a rigid support that fits over the cell culture cassette. The side assemblies joined by a hinge at one end and positioned over the two side walls of the cell culture cassette. The apparatus further contains a means to secure the two side assemblies over the two side walls of the cell culture cassette.
Type:
Grant
Filed:
December 20, 2004
Date of Patent:
October 14, 2008
Assignee:
Memorial Sloan-Kettering Cancer Center
Inventors:
Gene R. Diresta, John H. Healey, Robert Schwar
Abstract: An apparatus for growing cells in a 2-D cell cassette having a matrix for cell growth under pressure comprising two side assemblies which include a frame with a rigid support that fits over the 2-D cell cassette, with said assemblies positioned on either side of the cassette over the solid support sides, and a means to secure the sides of the cassette. The invention also provides different uses of this apparatus.
Type:
Grant
Filed:
March 3, 2003
Date of Patent:
September 9, 2008
Assignee:
Memorial Sloan-Kettering Cancer Center
Inventors:
Gene R. Diresta, John H. Healey, Robert Schwar
Abstract: The invention relates to a cardiopulmonary bypass pump that can be used with medication to put the heart into asystole or near asystolic status. The patent describes equipment used in conjunction with medication to temporarily replace the function of the heart and to allow the heart to survive with minimal oxygen supply for hours or days, and for the heart to recover from ischemic or other insult or other damage without being subjected to a heavy working load. The invention provides a means to stop blood flow to the heart for a relatively long period of time, thereby allowing the performance of certain procedures that require coronary artery blockade. It also allows the heart to stop contracting, which may result in safer and easier performance of some procedures. A medication is given to the patient while the device is in use in order to stop the heart or slow the heart rate to a minimal level to decrease cardiac oxygen requirements without significant hemostasis in the pulmonary circulation.